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US-Guided Vacuum-Assisted Biopsy of
Microcalcifications in Breast Lesions and
Long-Term Follow-Up Results
Objective: To evaluate the diagnostic accuracy of the use of an ultrasonogra-
phy (US)-guided vacuum-assisted biopsy for microcalcifications of breast lesions
and to evaluate the efficacy of the use of US-guided vacuum-assisted biopsy with
long-term follow-up results.
Materials and Methods: US-guided vacuum-assisted biopsy cases of breast
lesions that were performed between 2002 and 2006 for microcalcifications were
retrospectively reviewed. A total of 62 breast lesions were identified where further
pathological confirmation was obtained or where at least two years of mammog-
raphy follow-up was obtained. These lesions were divided into the benign and
malignant lesions (benign and malignant group) and were divided into underesti-
mated group and not-underestimated lesions (underestimated and not-underesti-
mated group) according to the diagnosis after a vacuum-assisted biopsy. The
total number of specimens that contained microcalcifications was analyzed and
the total number of microcalcification flecks as depicted on specimen mammog-
raphy was analyzed to determine if there was any statistical difference between
the groups.
Results: There were no false negative cases after more than two years of fol-
low-up. Twenty-nine lesions were diagnosed as malignant (two invasive carcino-
mas and 27 carcinoma in situ lesions). Two of the 27 carcinoma in situ lesions
were upgraded to invasive cancers after surgery. Among three patients diag-
nosed with atypical ductal hyperplasia, the diagnosis was upgraded to a ductal
carcinoma in situ after surgery in one patient. There was no statistically significant
difference in the number of specimens with microcalcifications and the total num-
ber of microcalcification flecks between the benign group and malignant group of
patients and between the underestimated group and not-underestimated group of
patients.
Conclusion: US-guided vacuum-assisted biopsy can be an effective alterna-
tive to stereotactic-guided vacuum-assisted biopsy in cases where microcalcifica-
tions are visible with the use of high-resolution US.
n image-guided percutaneous biopsy is currently recognized as a reliable
alternative to an excisional biopsy for the histopathological diagnosis of
breast lesions (1-3). Moreover, vacuum-assisted devices provide larger
core samples and allow more contiguous sampling than the use of automated guns,
potentially leading to more complete sampling of the targeted lesions and reducing the
chances of sampling error (4). For the guiding method, ultrasonography (US) guidance
may be preferable in lesions that are amenable to biopsy with either stereotactic or US
guidance as US guidance offers a number of advantages over the use of stereotactic
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Aguidance (5, 6). Although US guidance has some critical
limitations in biopsies for a mammographic abnormality
such as the presence of microcalcifications without a mass,
there are conditions when a percutaneous stereotactic
biopsy is not available or not accessible. For example, for
lesions in thin breast tissue, too close to the chest wall or in
the breast tissue of axillary tail, the procedure could or
should be converted to a US-guided procedure if possible
(7). Following a review of the published literature, there
has been no study on the efficacy of US-guided vacuum-
assisted biopsy (VAB) for microcalcifications. This study
was designed to evaluate the diagnostic accuracy of US-
guided VAB (US-VAB) for microcalcifications in breast
lesions and its efficacy with long-term follow-up results.
MATERIALS AND METHODS
Our institutional review board approved this research
study, and waived the requirement for informed consent,
as the study was retrospective.
Study Population
Between February 2002 and February 2006, 834
percutaneous US-VABs of consecutive breast lesions in
patients were performed in our institution using the
Mammotome system (Biopsys/Ethicon Endo-Surgery,
Cincinnati, OH). We reviewed the clinical and imaging
findings of 837 consecutive lesions and 736 lesions from
patients that underwent a VAB for mass or architectural
distortion were excluded from the study. After a review of
follow-up imaging and the pathological findings of the
remaining 101 lesions, we further excluded 39 lesions from
patients who did not receive follow-up for at least two
years nor underwent further pathological confirmation of
the lesions. The remaining 62 lesions from patients who
had undergone a VAB due to the presence of microcalci-
fications as depicted on mammography and then had
received at least two years follow-up or underwent
excision for pathological confirmation of the lesions were
included in this study. Among the patients with the 62
lesions, three patients underwent a VAB for each breast as
they presented with microcalcifications in both breasts.
Finally, 62 lesions of 59 patients were included in this
study.
The mean age of the 59 patients was 46.7 years (age
range, 27 to 70 years). The patients underwent mammog-
raphy for various reasons. Three patients had a nipple
discharge and another three patients complained of the
presence of palpable lesions. One patient had an incidental
finding of increased flurodeoxyglucose (FDG) uptake on
the breast on a PET scan. Fifty-two patients had mammog-
raphy performed for routine breast cancer screening.
Imaging Evaluation
Mammography was performed with dedicated
equipment (DMR; General Electric Medical Systems,
Milwaukee, WI) until April 2005 and a Lorad/Hologic
Selenia Full Field Digital Mammography System
(Lorad/Hologic, Danbury, CT) from May 2005 onwards.
Standard craniocaudal and mediolateral oblique views
were routinely obtained and additional mammographic
views were obtained as needed. All of the cases underwent
mammography. Digital mammography was performed for
29 lesions and film mammography was performed for 33
lesions.
Ultrasonography was performed using a high-resolution
US unit (HDI 5000, Philips-Advanced Technology
Laboratories, Bothell, WA) with 12-MHz linear array
transducers. Prior to a VAB, lesions were assigned to the
final assessment categories of the Breast Imaging Reporting
and Data System (BI-RADS) based on the findings of
mammography and sonography (8) and data was entered
prospectively into a database using a computerized spread-
sheet (Excel, Microsoft, Redmond, WA).
The microcalcification management protocol in our
institution is the following. A US-guided automated core-
needle is used for microcalcifications with an associated
mass lesion. A US-VAB is used for microcalcifications
visible by US but without an associated mass lesion. An
excisional biopsy is used after mammography-guided
needle localization for microcalcifications that cannot be
delineated by US. Except in cases where a patient or
clinician requested a different procedure, all of the lesions
included in this study were managed according the above
protocol.
US-Guided Vacuum-Assisted Biopsy and Management
After a meticulous US examination, a BB marker was
placed on the skin above suspicious microcalcifications and
the patient underwent mammography to assure that the
calcification noted on US was consistent with the
suspicious calcification depicted on mammography. The
VAB procedure was performed by one of two board-
certificated radiologists with four and 10 years experience
in breast imaging, respectively. After administration of
local anesthesia, an 11-gauge probe was inserted into the
breast through a small skin incision and was guided into
the biopsy position under direct ultrasound visualization
(HDI 5000). Multiple core samples were taken until the
suspected microcalcifications were invisible on US. After
the VAB, specimen mammography was taken in every
case to ensure that the aimed microcalcifications were
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without calcification were sent for a pathological examina-
tion separately.
In cases where the pathological diagnosis was
malignancy or borderline lesions such as atypical ductal
hyperplasia (ADH), surgical resection was recommended.
In the case of a benign finding where calcification was
confirmed by specimen mammography with concordant
imaging-pathological diagnosis, follow-up mammography
in six months, 12 months and 24 months intervals were
recommended. When the imaging-histological diagnosis
was discordant or the histological diagnosis was benign but
without calcification as depicted on specimen mammogra-
phy, excision under mammographic localization was
recommended.
Follow-Up and Data Analysis
The clinical, pathological and imaging findings of the 62
lesions, including the results of subsequent excisions and
follow-up imaging studies, were reviewed. For four lesions,
mammography films were not available and we reviewed
the original mammography report instead. With respect to
the follow-up data, we evaluated whether there was
histological underestimation or a false-negative result at
follow-up. Histological underestimation included a VAB-
diagnosed ductal carcinoma in situ (DCIS) that was later
revealed as an invasive carcinoma and a VAB-diagnosed
ADH that was later revealed as an DCIS or invasive
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Fig. 1. 44-year-old female who
underwent mammography for routine
breast screening.
A. Magnification view of left breast
reveals suspicious clustered and
pleomorphic microcalcification (white
arrow).
B. Careful US study of left breast shows
microcalcification of suspicion (white
arrows) in left upper central aspect.
C. Patient underwent 11 gauge US-
guided vacuam-assisted biopsy targeted
at microcalcification.
D. Specimen mammography shows that
aimed microcalcification is retrieved
(white arrows). Patient was diagnosed
with ductal carcinoma in situ and
underwent further partial mastectomy,
which also revealed presence of ductal
carcinoma in situ.
Dcancer by surgery. The underestimation rate was
determined from dividing the number of lesions with
underestimation in the final diagnosis by the total number
of lesions with ADH or DCIS as determined after a VAB.
A false negative was defined as the final diagnosis being
malignancy with a benign diagnosis as determined by a
VAB. The false negative rate was determined by dividing
the number of lesions with a false negative result in the
final diagnosis by the total number of VABs performed.
We reviewed the specimen mammography findings and
assessed the average number of specimen samples with its
range and standard deviation. We also estimated the
number of specimens containing microcalcifications out of
the total number of specimens and the number of microcal-
cifications to examine the efficacy of the use of US-VAB to
retrieve a targeted microcalcification. When the total
number of microcalcifications was greater then 100, it was
referred to as ‘innumerable’. We analyzed the number of
microcalcifications and the number of the core specimens
containing microcalcifications to determine if there was
any statistically significant difference between lesions
identified as benign and malignant. The Chi-squared or
Fisher’s exact tests for nonparametric variables and the t-
test for parametric inference were performed. Statistical
analysis was performed with SAS software (SAS system
for Windows, version 9.0 SAS Institute, Cary, NC).
RESULTS
Mammography
All the patients were seen with a heterogeneously dense
fibroglandular background on mammography. The
BIRADS category of each patient is shown in Table 1. The
extent of microcalcifications was assessed by measuring the
longest diameter of the microcalcification distribution on
routine mammography. The average diameter was 2.8 cm
with a range from 0.5 cm to 8.6 cm and a standard
deviation of 2.0 cm.
Pathological Diagnosis and Follow-Up
Twenty-nine out of 62 lesions were identified as a breast
malignancy (Fig. 1). Twenty-seven lesions were identified
as DCIS by VAB and two lesions were identified as
invasive ductal carcinoma (IDC). The remaining 33 lesions
were benign (Table 2). Three of the patients had ADH.
Patients with the 29 malignant lesions underwent a
mastectomy or breast conservation surgery. The pathologi-
cal results after surgery revealed the presence of an IDC
for two lesions of a VAB-diagnosed DCIS. The underesti-
mation rate was 7.4%. One patient who was diagnosed
with a DCIS showed no residual cancer after surgery and
all of the other patients had a residual malignancy as
identified in the pathological specimens. Nine lesions had
residual microcalcifications that were confirmed in the
pathological specimens.
The three patients who were diagnosed with ADH
underwent excision for further pathological confirmation.
One of the lesions from the patients was discovered to
have a DCIS component. The remaining two patients were
diagnosed with ADH with no residual atypia. The ADH
underestimation rate was 33.3%.
Five other lesions from patients diagnosed with benign
disease by VAB underwent excision. For two lesions, the
patients wanted the lesions excised, as the lesions were
palpable although they were imaging-histologically concor-
dant. Another three lesions showed an increased number
of microcalcifications on follow-up mammography. The
follow-up period was 10 months, 23 months and 25
months, respectively with an average of 19.3 months. The
lesions were excised after mammographically guided
localization; all of the lesions were finally identified with a
fibrocystic change with microcalcifications. 
In addition to the five lesions that underwent excision
with a pathological diagnosis of benign disease other than
ADH after a VAB, the remaining 25 lesions had long-term
follow-up results of more than two years. On follow-up
mammography, there were no residual microcalcifications
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Table 1. BIRADS Category of 62 Lesions with
Microcalcifications
Category Number Percentage (%)
3 04 04.8
4a 21 33.8
4b 24 38.7
4c 09 14.5
5 04 04.8
Note.─ BIRADS = Breast Imaging Reporting and Data System
Table 2. Pathology from VAB Specimens
Pathological Diagnosis Number of Lesions
Invasive ductal carcinoma 02
Ductal carcinoma in situ 27
Fibrocystic change 18
Atypical ductal hyperplasia 03
Columnar cell change/hyperplasia 03
Stromal fibrosis 02
Ductal epithelial hyperplasia  02
Adenosis 02
Mucocele like lesion 02
Fibroadenoma  01
Note.─ VAB = vacuum-assisted biopsy seen in four lesions and the remaining 21 lesions showed
residual microcalcifications. There were no additional cases
of malignancy after more than two years of follow-up. The
false negative rate was 0%.
Specimen Mammography
We were able to examine specimen mammography in all
58 lesions except for four patients where mammography
films were not available. The average number of VAB
specimens per lesion was 9.6 specimens, ranging from
three to 19 specimens with a standard deviation of 3.2.
The number of specimens with microcalcifications ranged
from 0 to 16, with an average of 4.5 specimens with
microcalcifications seen on specimen mammography. The
percentage of the number of specimens with microcalcifica-
tions above the total was 46.9%. The average number of
microcalcifications was 43.8 countable microcalcification
flecks ranging from 0 to over 100. It was possible to
validate microcalcifications on specimen mammography
(Fig. 1) in all cases except for two lesions. One lesion was
identified with DCIS after VAB and though we could not
validate the presence of microcalcifications on specimen
mammography, pathology revealed a DCIS with microcal-
cifications. The patient underwent a mastectomy and the
final diagnosis was DCIS. The other lesion was from a
patient who had a probably benign lesion with microcalci-
fications in the right breast and a lesion with low suspicious
segmental microcalcifications in the left breast. US-VAB
was planned for the low suspicious lesion in the left breast
but the patient also wanted confirmation of the probably
benign lesion in the right breast. After VAB of both
lesions, specimen radiography showed microcalcifications
in the left breast while there were no microcalcifications in
the right breast. Both lesions were identified as a fibrocys-
tic change but there was no documentation of microcalci-
fications in the right breast on the pathology report. This
patient has received follow-up without further pathological
confirmation for more than four years and there has been
no significant interval change.
The number of underestimated lesions (n = 3) was too
small to statistically compare to the number of not-
underestimated lesions (n = 59) and the total number of
specimens, the number of specimens containing microcalci-
fications and the number of microcalcifications are shown
in Table 3.
There was no significant statistical difference in the total
number of specimens, the number of specimens containing
microcalcifications and the number of microcalcifications
between benign lesions and malignant lesions (Table 4).
DISCUSSION
The increasing use of mammographic screening has led
to the detection of smaller, earlier-stage malignancies,
which most often present as microcalcifications (9, 10).
Microcalcifications detected on mammography represent a
confounding situation as although the finding is the most
common mammographic finding of DCIS (10), at the same
time it is a very common finding in aging women. The
majority of lesions of screening-provoked surgical biopsies
that are ultimately identified as benign are due to calcifica-
tions (11). For decades, the use of the needle-localized
biopsy was accepted as the standard choice for a biopsy of
calcification detected on mammography (12, 13).
However, as the imaging equipment has evolved and the
biopsy skills have accumulated, the use of the image-
guided percutaneous biopsy became an another alternative
(14). Moreover, when the patient condition is not adequate
to undergo general anesthesia or when there is no stereo-
tactic biopsy unit available, as in our institution, the use of
US VAB can be helpful if the microcalcifications can be
delineated by US (7). In addition, US guidance offers a
number of advantages over the use of stereotactic
guidance. The patient is in supine position rather than a
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Table 3. Number of Specimens According to Estimation
Underestimated (n = 3) Not-underestimated (n = 59)
Average total number of specimens 7 09.8
Average number of specimens with calcification 03.3 04.5
Average total number of calcifications 32.3 33.2
Table 4. Number of Specimens According to Diagnosis
Benign (n = 33) Malignancy (n = 29)
Average total number of specimens 09.2 10.1
Average number of specimens with calcification 03.8 05.3
Average total number of calcifications 31.1 37.4prone position. Moreover, there is no need for compres-
sion. There is no radiation hazard. The image acquisition is
in real-time. Furthermore, the equipment is more afford-
able and readily available.
A shortcoming of US is that microcalcifications are not
depicted as clearly as in mammography. However, as the
high-resolution US equipment has evolved, the chance of
finding a microcalcification of question by careful US
examination has also increased (15). We were able to
confirm retrieved microcalcifications by specimen
mammography in 96.8% of cases, which is within the
range of 95% to 100% that was previously reported by
the use of successful stereotactic guided VAB (ST-VAB) for
microcalcifications (2, 16-18). Though there were two
lesions without microcalcifications seen on specimen
mammography, there was no case of missed diagnosis of
cancer in this study. The reported rate of a missed diagno-
sis of cancer after an ST-VAB is from 0% to 3% (19).
However, as microcalcifications are not well visualized on
US as in mammography, to apply US-VAB in cases of
microcalcifications, a meticulous US examination by an
experienced operator is mandatory and the insertion of a
retrievable wire can be also helpful (20) to locate a
microcalcification of question. The underestimation rate
for a carcinoma was 7.4% in the current study with two of
the DCIS lesions identified as an IDC and one of the DCIS
lesions identified as a DCIS with microinvasion. In past
studies, the underestimation rate of the use of an ST-VAB
for a carcinoma was reported from 18% to 20% (16, 21).
In the case of an ADH identified after a VAB, surgical
excision was recommended, as over 50% of ADH lesions
are known to have a carcinoma at the time of excision (21,
22). The underestimation rate for an ADH was 33.3%, one
cancer out of three ADH lesions in the current study,
which is within the recently reported range of 7% to 35%
after an ST-VAB.
There was no statistical difference in the number of the
specimen cores with microcalcifications and the total
number of microcalcifications between the malignant
lesions and benign lesions in this study. This result suggests
that the efficacy of a US-VAB for microcalcifications is
independent of the nature of the lesion as being malignant
or benign.
In the case of a stereotactic-automated core-needle-
biopsy, at least five or more flecks of calcium or three or
more cores containing calcium are necessary to be present
to ensure adequate sampling of microcalcifications with
increasing retrieval of calcification that is associated with
increasing sensitivity (23). In this study, the average
number of specimens with microcalcifications was 4.5
specimens, ranging from 0 to 16 specimens with a mean
number of 43.8 calcification flecks and there was no statis-
tically significant difference between benign lesions and the
malignant lesions. This finding is concordant with a
previous report with the use of automated core needle
biopsies. The amount of microcalcification retrieval after a
VAB in this study was higher than that required for an
automated core-needle-biopsy, which may explain why
there was no statistically significant difference between the
malignant lesions and benign lesions. To the best of our
knowledge, there has been no previous report of an
adequate amount of microcalcification retrieval after a US-
VAB. However, it has been reported that in the case of an
ST-VAB, to yield 92% of diagnostic accuracy, 12
specimens were necessary and we obtained an average of
9.6 specimens in this study.
This study only included patients with lesions that
received follow-up for at least two years or patients that
underwent surgery for further confirmation. A previous
study on the use of an ST-VAB for breast microcalcifica-
tions has suggested that a 6-month follow-up might already
provide evidence that a VAB finding is representative (19).
In the case of US-VAB for microcalcifications, given the
limitations of the use of US for visualization of microcalci-
fications, long term follow up with mammography longer
than six months should be necessary. In the case of a core
needle biopsy, a two-year-follow-up is generally accepted
to make a confident diagnosis of benign disease (19) and
hence a follow-up period of more than two years can
ensure a confident diagnosis for a US-VAB of breast
microcalcifications.
There are some limitations to this study. First, only
microcalcifications visible on linear probe US were
included in this study and thus the study does not reflect all
of the microcalcifications, including microcalcifications not
delineated by US. Second, patients without a follow-up
period longer than two years were excluded in this study
and there could be a possible missed diagnosis in these
patients. Also, we set a standard follow-up period of at
least two years, which may be insufficient to diagnose a
lesion with microcalcifications as benign and a further
follow-up would be necessary.
In conclusion, the use of a US-VAB can be an effective
alternative to the use of an ST-VAB in cases where
microcalcifications are visible on high-resolution US.
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